Trio Plans Anti-COVID-19 Vaccine Derived From Simian Adenoviruses
Comprises Italy’s ReiThera, Germany’s Leukocare, Belgium’s Univercel
Three European biotechs have joined forces to develop and manufacture a simian adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.
You may also be interested in...
The UK government is proposing to take the "very unusual step" of making COVID-19 vaccines available before they are licensed. The international COVAX initiative is now supporting nine vaccines, and the EU and AstraZeneca have firmed up a vaccine purchase agreement.
GlaxoSmithKline has acquired Swiss vaccine developer Okairos for €250 million in cash. The privately held firm was spun out of Merck & Co in 2007.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.